<DOC>
	<DOCNO>NCT00834080</DOCNO>
	<brief_summary>The purpose study determine safety tolerability Medisorb速 naltrexone ( VIVITROL速 ) administer period 24 month health care professional history opioid dependence .</brief_summary>
	<brief_title>ALK21-021 : A Safety Study Medisorb速 Naltrexone ( VIVITROL速 ) Administered Health Care Professionals</brief_title>
	<detailed_description />
	<mesh_term>Opioid-Related Disorders</mesh_term>
	<mesh_term>Analgesics , Opioid</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>Primary Health care professional ( eg , physician , osteopath , nurse , pharmacist ) 18 year age old Enrolled enrol extended outpatient treatment program opioid dependence Women childbearing potential must agree use approve method contraception duration study Primary Pregnancy and/or lactation Evidence hepatic failure Active hepatitis Any psychiatric disorder would compromise ability complete study requirement Recent history suicidal ideation attempt Current dependence drug prescription opioids heroin , benzodiazepine , caffeine , marijuana , alcohol , nicotine Positive urine drug test selfreported use opioids , cocaine , amphetamine screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>opioid dependence</keyword>
	<keyword>VIVITROL</keyword>
	<keyword>opioid-related disorder</keyword>
</DOC>